Amgen announces new FOURIER analysis showing Repatha® (evolocumab) reduced cardiovascular events in patients with prior percutaneous intervention at AHA 2020
The FOURIER analysis showed that Repatha reduced the risk of major coronary events by 18% in patients with prior PCI, who were at a high risk for CV events. This analysis demonstrates the benefit of PCSK9 inhibition with evolocumab in reducing major coronary events.